Cetera Advisors LLC increased its stake in shares of Novartis AG (NYSE:NVS) by 16.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,197 shares of the company’s stock after purchasing an additional 856 shares during the quarter. Cetera Advisors LLC’s holdings in Novartis were worth $534,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. WFG Advisors LP raised its stake in Novartis by 38.1% in the second quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock valued at $102,000 after buying an additional 337 shares during the last quarter. Wealthcare Advisory Partners LLC purchased a new stake in Novartis in the third quarter valued at about $106,000. Cable Hill Partners LLC raised its stake in Novartis by 588.8% in the third quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock valued at $112,000 after buying an additional 1,107 shares during the last quarter. Harding Loevner LP purchased a new stake in Novartis in the second quarter valued at about $146,000. Finally, Mosaic Family Wealth LLC raised its stake in Novartis by 6.1% in the second quarter. Mosaic Family Wealth LLC now owns 2,144 shares of the company’s stock valued at $179,000 after buying an additional 123 shares during the last quarter. Hedge funds and other institutional investors own 10.87% of the company’s stock.
Shares of Novartis AG (NYSE NVS) traded down $0.19 on Friday, reaching $84.47. The company’s stock had a trading volume of 890,900 shares, compared to its average volume of 2,242,544. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08. Novartis AG has a one year low of $69.53 and a one year high of $86.90. The firm has a market capitalization of $200,271.28, a price-to-earnings ratio of 17.82, a P/E/G ratio of 2.69 and a beta of 0.73.
Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, beating the consensus estimate of $1.25 by $0.04. Novartis had a return on equity of 15.77% and a net margin of 13.73%. The company had revenue of $12.41 billion for the quarter, compared to analyst estimates of $12.21 billion. During the same period last year, the company earned $1.23 earnings per share. Novartis’s quarterly revenue was up 2.4% compared to the same quarter last year. analysts anticipate that Novartis AG will post 4.75 earnings per share for the current fiscal year.
A number of research firms have commented on NVS. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis in a research note on Tuesday, September 26th. Zacks Investment Research cut Novartis from a “buy” rating to a “hold” rating in a research note on Thursday, September 21st. Leerink Swann raised their price objective on Novartis from $89.00 to $91.00 and gave the stock a “market perform” rating in a research note on Monday, October 23rd. Bank of America cut Novartis from a “neutral” rating to an “underperform” rating in a research note on Wednesday, December 6th. Finally, Barclays cut Novartis from an “equal weight” rating to an “underweight” rating in a research note on Wednesday, October 25th. Four analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have assigned a buy rating to the company. Novartis has a consensus rating of “Hold” and a consensus price target of $85.32.
ILLEGAL ACTIVITY NOTICE: This article was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://transcriptdaily.com/2017/12/15/cetera-advisors-llc-purchases-856-shares-of-novartis-ag-nvs.html.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.